Lentigen has named Adam Sachs to the newly created position of president of commercial operations, where he will lead efforts to market the firm’s lentiviral platform, the company said.
Sachs comes to Lentigen having spent 15 years in the biotech field, most recently as a molecular biology product development executive at Life Technologies, which is now Invitrogen.
Sachs also was director of manufacturing at Qiagen and vice president of operations at OriGene Technologies.
The Analytical and Life Science Systems Association, a trade group for product makers and marketers in the life sciences, has appointed Eksigent president and CEO David Weber to its board of directors, Eksigent said.
Before joining Eksigent Weber served as vice president of global marketing and business development for Stratagene and was president of the Americas at Amersham Biosciences.